MiMedx still a top pick, says Canaccord Canaccord reiterated its Buy rating and top pick designation for MiMedx following the company's raised guidance. The firm believes fundamentals are in place to drive execution in wound care for the foreseeable future as the company's increase in sales force remains ahead of plan and reimbursement changes support growth and increased expectations. Canaccord has a $12 price target on the stock.
MiMedx upgraded to Strong Buy with $13 target at Needham Needham upgraded MiMedx to Strong Buy from Buy saying it has renewed confidence the company can exceed consensus 2015 estimates after meeting with management. The firm has a $13 price target for shares.